Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping cancer spots could delay stronger drugs

NCT ID NCT04299646

Disease control Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether high-dose, precise radiation (stereotactic radiotherapy) can control a few growing kidney cancer spots while the rest of the disease is stable on current medication. About 77 people with metastatic kidney cancer whose tumors are progressing in only a few places will receive radiation to those spots. The goal is to see if this can delay the need to switch to a new, often stronger, systemic therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stereotactic radiotherapy
What this could lead to
If it works, this approach could help people with kidney cancer stay on their current treatment longer and delay switching to harsher drugs.
What could go wrong
This is a small, early-phase study with only 77 participants. It may not prove effective, and radiation can cause side effects like fatigue or local tissue damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 77 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2020

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clear cell renal cancer histologically proved (association with other histologic component are permitted) * Patients of good or intermediate prognostic, according to Heng criteria * Extracerebral metastatic disease documented with imagery * Patients treated in first or second line systemic therapy * Systemic treatment may be targeted therapies (tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors) and/or immunotherapy according to French applicable standards; patients treated in a clinical trial are also eligible if allowed by trial sponsor * Oligoprogressive disease documented with imagery, defined as the emergence or progression of 1 to 3 metastases and progression localized in up to 2 organs * Oligoprogressive disease confirmed with 2 CT scans performed 2 months apart * At least one measurable progressing metastasis according to R.E.C.I.S.T. criteria v1.1 * All oligoprogressive target lesions measuring ≤ 4 cm * Good general condition (WHO performance status ≤ 2) * All progressive lesions have to be accessible to SRT, performed concurrently or sequentially * No contraindication to systemic therapy and stereotactic radiation therapy * Patients aged 18 years or older * Signed informed consent form * Patients affiliated to the social security system Exclusion Criteria: * More than 3 progressive metastases * Non measurable disease according R.E.C.I.S.T. criteria * Patients who received 3 or more lines of systemic therapy * Inability to treat all progressive metastatic sites with SRT * Previous radiation therapy performed in ≥ 1 target lesion * At least 1 oligoprogressive target lesion measuring \> 4 cm * Presence of brain metastases * Presence of ultra-central pulmonary metastasis * Progressing metastasis in a long bone * At least 1 progressive metastasis requiring surgical treatment * Current or past history of second neoplasm diagnosed within the last 5 years * Pregnancy or breast feeding or inadequate contraceptive measures * Patients who cannot be adequately followed up * Patient deprived of freedom or under guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic renal cell carcinoma Radiotherapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHD Vendée

    NOT_YET_RECRUITING

    La Roche-sur-Yon, France

  • CHR

    NOT_YET_RECRUITING

    Metz, France

  • CHU Henri Mondor

    NOT_YET_RECRUITING

    Créteil, France

  • CHU La Timone

    NOT_YET_RECRUITING

    Marseille, France

  • Centre Antoine Lacassagne

    NOT_YET_RECRUITING

    Nice, France

  • Centre François Baclesse

    RECRUITING

    Caen, 14076, France

  • Centre Georges François LECLERC

    NOT_YET_RECRUITING

    Dijon, France

  • Centre Haute Energie

    NOT_YET_RECRUITING

    Nice, France

  • Centre Henri Becquerel

    NOT_YET_RECRUITING

    Rouen, France

  • Centre Hospitalier Annecy Genevois

    NOT_YET_RECRUITING

    Pringy, France

  • Centre Jean Perrin

    NOT_YET_RECRUITING

    Clermont-Ferrand, France

  • Centre Léon Bérard

    NOT_YET_RECRUITING

    Lyon, France

  • Centre Oscar Lambret

    RECRUITING

    Lille, France

  • Centre de radiothérapie Guillaume le Conquérant

    NOT_YET_RECRUITING

    Le Havre, France

  • Centre marie Curie

    RECRUITING

    Valence, France

  • Clinique Claude Bernard

    NOT_YET_RECRUITING

    Albi, France

  • Groupement de radiothérapie Oncologie des Pyrénées

    NOT_YET_RECRUITING

    Pau, France

  • ICM

    NOT_YET_RECRUITING

    Montpellier, France

  • IUCT

    NOT_YET_RECRUITING

    Toulouse, France

  • Institut Bergonié

    NOT_YET_RECRUITING

    Bordeaux, France

  • Institut Curie

    NOT_YET_RECRUITING

    Paris, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, France

  • Institut Paoli Calmette

    NOT_YET_RECRUITING

    Marseille, France

  • Institut de Cancérologie de Lorraine

    NOT_YET_RECRUITING

    Nancy, France

  • Institut de Cancérologie de l'Ouest

    RECRUITING

    Angers, France

  • Institut de Cancérologie de l'Ouest

    RECRUITING

    Nantes, France

  • Institut de Cancérologie de la Loire Lucien Neuwirth

    NOT_YET_RECRUITING

    Saint-Etienne, France

  • Institut de cancérologie de Bourgogne (Dijon, Auxerre, Chalon sur Saône)

    RECRUITING

    Dijon, France

  • Polyclinique de l'Ormeau

    RECRUITING

    Tarbes, France

  • Radiothérapie Bordeaux Nord Aquitaine

    NOT_YET_RECRUITING

    Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.